Rizatriptan Benzoate Tablets, USP, 10 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: A...

FDA Drug Recall #D-0534-2025 — Class II — July 9, 2025

Recall Summary

Recall Number D-0534-2025
Classification Class II — Moderate risk
Date Initiated July 9, 2025
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Ascend Laboratories, LLC
Location Bedminster, NJ
Product Type Drugs
Quantity N/A

Product Description

Rizatriptan Benzoate Tablets, USP, 10 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877-262-18

Reason for Recall

CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

Distribution Pattern

US Nationwide.

Lot / Code Information

Lot 22143653, 22143675, Exp Date: July 2025; Lot 22144528, Exp Date: September 2025; Lot 22144977, Exp Date: November 2025; Lot 23140257, Exp Date: December 2025; Lot 23140999, Exp Date: Feb. 2026; Lot 23141900, 23142118, 23142120, 23142123, Exp Date: May 2026; Lot 23144563, 23144565, Exp Date: November 2026; Lot 24142623, Exp Date: May 2027; Lot 24142624, 24142626, 24143469, Exp Date: Jun. 2027.

Other Recalls from Ascend Laboratories, LLC

Recall # Classification Product Date
D-0017-2026 Class II Atorvastatin Calcium Tablets USP, 10 mg, Rx Onl... Sep 19, 2025
D-0020-2026 Class II Atorvastatin Calcium Tablets USP, 80 mg, Rx Onl... Sep 19, 2025
D-0019-2026 Class II Atorvastatin Calcium Tablets USP, 20 mg, Rx Onl... Sep 19, 2025
D-0018-2026 Class II Atorvastatin Calcium Tablets USP, 40 mg, Rx Onl... Sep 19, 2025
D-0645-2025 Class II Aripiprazole Tablets, USP, 10 mg, 30-count bott... Aug 28, 2025

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.